Will there be any effects after discontinuation of selegiline/imidopir?

Selegiline/imidopyr(Selegiline) is a selective monoamine oxidase B (MAO-B) inhibitor, mainly used for the treatment of Parkinson's disease. Its mechanism of action is to inhibit the degradation of dopamine in the brain and increase the availability of dopamine between nerve synapses, thereby improving motor function. Whether there will be any effects after stopping the drug is a common concern among patients, and it needs to be analyzed from the perspectives of pharmacological effects, clinical manifestations and long-term management.

From a pharmacological mechanism perspective, selegiline inhibitsMAO-B enzyme activity, delays the degradation of dopamine, and improves Parkinson’s symptoms. When a patient suddenly stops taking medication, dopamine levels in the body will gradually return to the baseline state before stopping the medication, which may lead to aggravation of motor symptoms, especially for middle- and late-stage patients who originally rely on medication to control symptoms. Symptoms may appear as worsening tremors, stiffness, slowed movements, or “on-off” fluctuations, which are not caused by drug dependence but are the natural progression of the disease itself after the drug is withdrawn.

Stopping medication may have some impact on your mental state. By increasing dopamine and phenylethylamine activity, selegiline may produce a mild mood lift and improved energy in some patients. After stopping the drug, this slight central stimulating effect disappears, and patients may experience short-term decreased concentration, fatigue, or mild depression, but these are usually not serious psychological symptoms, nor will they cause addiction or withdrawal symptoms.

In terms of clinical management, doctors usually recommend gradual dose reduction rather than sudden discontinuation to reduce fluctuations in motor symptoms and mood changes. For patients taking selegiline long-term, gradual dose tapering can help the body adjust to changes in dopamine levels while providing a buffer for adjustments to levodopa or other Parkinson's disease medications. This method is widely recommended in overseas guidelines and is especially suitable for patients in the intermediate and advanced stages or patients who are combined with other central nervous system drug treatments.

Reference: https://www.drugs.com/mtm/selegiline.html